Clinical trial · Observational
Detecting EGFR T790M Mutations From Circulating Tumor Cells
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this research study is to determine if the EGFR mutation can be detected in CTCs. CTCs are cancer cells that are shed from solid tumors and float freely in the bloodstream. A device called the CTC-chip has been developed to find CTCs in the blood of patients with cancer. This is an experimental device. Using this device, the investigators will test participants' blood to try and find CTCs with the EGFR mutation and compare them with the results from the biopsy your doctor has recommended. The long-term goal of this research is to develop a way to test for the EGFR mutation that is less invasive than a tumor biopsy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Circulating tumor cell chip | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- NSCLC
- description
- Subjects with advanced NSCLC, will undergo blood draw
- interventionNames
- Device: Circulating tumor cell chip
Primary outcomes (2)
- measure
- Number of patients with detectable EGFR mutations in their CTCs
- timeFrame
- 2 years
- description
- Calculate the number of patients in the study population with detectable EGFR mutations in the CTCs in order to demonstrate the feasibility of testing for EGFR mutations from captured CTCs
- measure
- Number of patients with CTC-derived EGFR genotyping matching their tumor-derived EGFR genotyping
- timeFrame
- 2 yearss
- description
- Determine the concordance of EGFR genotyping from CTCs compared to tumor tissue
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed NSCLC that is metastatic or unresectable * Have agreed to undergo a clinically recommended invasive repeat tumor itssue biopsy Exclusion Criteria: \-
References
Publications (0)
Data not yet available